FPO 2D 40027642 ® ()

weight; dogs, 2.5 mg/lb of body weight. The following table may be ® used as a guide: Dosage Schedule (epsiprantel) Feline Body Weight Dose Seven weeks old Veterinary Tablets up to 10 lb 12.5 mg 11–20 lb 25.0 mg Cestex (epsiprantel) tablets are indicated for the removal of tapeworms Canine in the cat ( and taeniaeformis) and dog Body Weight Dose (Dipylidium caninum and Taenia pisiformis). Seven weeks old up to 5 lb 12.5 mg CAUTION: Federal law restricts this drug to use by or on the order of 6–10 lb 25.0 mg a licensed veterinarian. 11–20 lb 50.0 mg DESCRIPTION: Cestex tablets are film-coated and contain 12.5 mg, 21–40 lb 100.0 mg 25 mg, 50 mg or 100 mg of epsiprantel per tablet. 41–50 lb 125.0 mg Epsiprantel is an that is active as a single dose against 51–60 lb 150.0 mg the common tapeworms of cats and dogs. Epsiprantel has a ­molecular 61–80 lb 200.0 mg weight of 326 and is chemically 2-(cyclohexyl-carbonyl)-4-oxo 1,2,3,4, 81–90 lb 225.0 mg 6,7,8,12b-octahydro­pyrazino[2,1-a][2]benza-zepine. It is a stable white 91–100 lb 250.0 mg solid which is sparingly soluble in water. Its chemical structure is pre­ 101+ lb 2.5 mg/lb, rounding up to next whole sented below. tablet combination Fasting is not necessary or recommended. Unless exposure to the infected intermediate hosts is controlled, reinfection is likely and retreatment may be required. In the case of D. caninum, an effective flea control program should be instituted. SAFETY: Epsiprantel has been evaluated in cats at 5 times the recom- mended dose given once daily for 3 days with no adverse effects noted. In tolerance studies, epsiprantel produced minimal clinical signs in cats given 40 times the recommended dose once daily for 4 days. Epsiprantel has been evaluated in 14-day repeat dose studies in dogs at 500 mg/kg (90 times recommended dosage) with no significant adverse results. No side effects were observed during the clinical field studies. Action: Epsiprantel acts directly on the tapeworm. Since it is mini­mally Epsiprantel is not a cholinesterase inhibitor. During the course of absorbed following oral administration, epsiprantel remains at the site ­clinical field studies, Cestex was administered concurrently with of action within the gastrointestinal tract. Due to digestive process, ­diethylcarbamazine citrate (dogs only), anti-inflammatory agents, tapeworm fragments or proglottids may not be readily visible in the insecticides, and nematocides with no drug incompatibilities noted. stool. STORAGE: Store at controlled room temperature 20°-25°C (68°-77°F) INDICATIONS AND USAGE: Cestex tablets are indicated for the with excursions between 15°-30°C (59°-86°F). removal of the following: HOW SUPPLIED: Cestex tablets are film-coated and contain 12.5 mg, Feline cestodes: Dipylidium caninum and Taenia taeniaeformis 25 mg, 50 mg or 100 mg of epsiprantel per tablet. Cestex is supplied as Canine cestodes: Dipylidium caninum and Taenia pisiformis described below: CONTRAINDICATIONS: There are no known contraindications to the Weight (lbs) Number use of this drug. Concentration Cat Dog Tablets/Bottle 12.5 mg 10 5 50, 100 WARNINGS: For use in cats and dogs only. Safety of use in pregnant 25.0 mg 20 10 50, 100 or breeding has not been determined. Keep out of reach of 50.0 mg – – 20 25, 50 children. Not for use in humans. 100.0 mg – – 40 25, 50 PRECAUTION: Do not use in kittens or puppies less than 7 weeks of age. Approved by FDA under NADA # 140-893 DOSAGE AND ADMINISTRATION: Cestex tablets should be adminis- tered orally. Distributed by: 40027642 The recommended dosage of epsiprantel is: cats, 1.25 mg/lb of body Zoetis Inc. Kalamazoo, MI 49007 Revised: May 2019

AWC Representative Plant Name / Code Artwork Center: US G. Woods Lincoln/US12 QN / Project No. FG Material No. New Material No. Description 200007437 Multiple 40027642 INS CESTEX TABS DIR No. / Version No. Specification / DWG Old Material No. Countries 509863 /00 Z21-11677001R01 P04-13915900 US Dimensions Colors 8.0” x 6.0” Folds to 2.0” x 1.0” BLACK Dieline Additional Info.

Visual Code Bar: 4, 5 Version No. Date

v1 40027642.indd 1 5/17/19 12:57 PM